Barrett’s Oesophagus

Many Australians live with persistent heartburn for years without realising it may have caused lasting changes to the lining of their oesophagus. Barrett’s oesophagus is one such change, a condition in which the normal cells of the lower oesophagus are gradually replaced by a different cell type, similar to those found in the stomach and intestine. While the condition itself is not cancer, it is recognised as a risk factor for a particular type of oesophageal cancer, and for that reason it warrants appropriate monitoring and specialist care.

What is Barrett’s Oesophagus?

The oesophagus is the muscular tube that carries swallowed food and fluid from the throat to the stomach. In a healthy oesophagus, the inner lining is made up of flat, pinkish-white cells called squamous cells, which are well suited to the mechanical task of moving food downward. The stomach lining, by contrast, is composed of taller cells that produce a protective mucus capable of withstanding the stomach’s acidic environment.

When stomach acid and digestive fluids repeatedly wash back into the lower oesophagus (a process known as gastro-oesophageal reflux), the squamous cells are exposed to a corrosive environment they are not designed to tolerate. Over time, this chronic exposure can lead to a process called intestinal metaplasia, in which the normal squamous cells of the lower oesophagus are replaced by a columnar cell type resembling the lining of the stomach and small intestine. This transformation is what is known as Barrett’s Oesophagus.

The condition was first described by the Australian-born surgeon Norman Barrett in 1957, and it remains an important area of gastroenterological practice. Under Australian clinical guidelines, a diagnosis of Barrett’s Oesophagus requires two things: first, endoscopic evidence of salmon-pink coloured columnar tissue extending above the junction where the oesophagus meets the stomach; and second, confirmation on tissue biopsy that intestinal metaplasia is present, characterised by the appearance of specialised goblet cells. The extent of the affected segment is measured and classified as short segment (less than three centimetres) or long segment (three centimetres or more), which has implications for surveillance intervals and cancer risk.

How common is it?

Barrett’s Oesophagus is more prevalent than many people realise. Population studies suggest it affects up to two per cent of the general community, meaning a significant number of Australians are living with the condition without knowing it. Because Barrett’s oesophagus produces no symptoms beyond those of ordinary reflux, many people remain undiagnosed unless they undergo an upper gastrointestinal endoscopy. The condition is approximately twice as common in men as in women, and prevalence increases with age.

Who is at risk of developing Barrett’s Oesophagus?

The strongest and most consistently identified risk factors for Barrett’s Oesophagus are chronic gastro-oesophageal reflux, male sex, increasing age, central obesity and cigarette smoking. People who have experienced reflux symptoms for more than five years face a meaningfully higher risk of developing the condition, and research has confirmed that symptoms of gastro-oesophageal reflux increase the risk of long-segment Barrett’s Oesophagus more than fivefold.

Central obesity, particularly excess fat around the abdomen, is an independent risk factor, and this association appears to exist even in people who do not experience obvious reflux symptoms. This suggests that metabolic factors, not just mechanical reflux, play a role in the development of the condition. Smoking has also been clearly implicated, increasing risk by approximately fifty per cent. A family history of Barrett’s Oesophagus or oesophageal adenocarcinoma in a first-degree relative is an additional consideration, as it may lower the threshold at which endoscopic assessment is warranted.

Interestingly, infection with Helicobacter pylori appears to reduce the risk of Barrett’s Oesophagus, though this does not mean H. pylori infection is desirable, as it carries its own significant health implications, including gastric ulcers and stomach cancer risk.

Symptoms of Barrett’s Oesophagus

Barrett’s Oesophagus does not produce a distinctive set of symptoms that would distinguish it from ordinary reflux. Most people with the condition experience the same symptoms as those with uncomplicated gastro-oesophageal reflux disease: persistent heartburn, a burning sensation in the chest or upper abdomen, regurgitation of stomach contents, and occasionally difficulty or discomfort with swallowing.

Because these symptoms are common and often treated without further investigation, Barrett’s oesophagus can go undetected for many years. A person who has lived with regular heartburn for an extended period and has never undergone an endoscopy may be unaware that cellular changes have already occurred. This is precisely why assessment is important for people with longstanding or poorly controlled reflux, particularly in the presence of other risk factors.

How is Barrett’s Oesophagus diagnosed?

The diagnosis of Barrett’s oesophagus can only be established through endoscopy combined with tissue biopsy. There is no blood test or imaging study that can confirm the condition.

Upper Gastrointestinal Endoscopy

An upper gastrointestinal endoscopy (also known as gastroscopy) involves passing a thin, flexible tube fitted with a light and a small camera through the mouth and down into the oesophagus, stomach, and upper part of the small intestine. This allows the gastroenterologist to directly inspect the lining of the oesophagus for the salmon-pink discolouration and columnar appearance characteristic of Barrett’s changes. The extent of the affected area is measured and documented according to standardised criteria.

During the same procedure, enhanced imaging techniques such as narrow band imaging or chromoendoscopy may be used. These methods alter the light used to illuminate the oesophageal lining, improving the visibility of abnormal tissue and helping to identify areas that may warrant closer sampling.

Biopsy

Biopsies are taken from within the columnar-lined segment during the endoscopy. Tissue samples are taken at regular intervals along the Barrett’s segment using a systematic protocol, and any areas of visible irregularity are sampled separately. A pathologist then examines the tissue under the microscope to confirm the presence of intestinal metaplasia and assess whether any degree of dysplasia is present. The biopsy findings are central to both confirming the diagnosis and guiding decisions about management and surveillance frequency.

Understanding cancer risk

The primary reason Barrett’s Oesophagus is taken seriously is its association with oesophageal adenocarcinoma, a cancer arising from the lower oesophagus. The incidence of oesophageal adenocarcinoma has risen substantially in Australia over the past four decades, and the vast majority of these cancers develop from an underlying Barrett’s segment.

However, it is important to place this risk in perspective. Earlier estimates of cancer progression were considerably higher than those established by more recent, population-based studies. Current data suggest that people with non-dysplastic Barrett’s oesophagus progress to cancer at a rate of approximately one to three per one thousand patient-years, meaning that the absolute annual risk for an individual with uncomplicated Barrett’s Oesophagus is low. The risk is greater in people with long-segment disease and in those whose biopsies show evidence of dysplasia.

Dysplasia refers to abnormal changes in the cells of the Barrett’s segment that indicate a higher likelihood of progression toward cancer. It is classified as low grade or high grade depending on the degree of cellular abnormality. High grade dysplasia carries a substantially greater risk of cancer development and requires prompt specialist assessment. The presence of dysplasia does not mean cancer is inevitable, but it does indicate the need for careful management and closer surveillance.

Surveillance and ongoing monitoring

For people diagnosed with Barrett’s Oesophagus, regular endoscopic surveillance is the cornerstone of ongoing management. The purpose of surveillance is to detect any progression of cellular changes at the earliest possible stage, when treatment options are most effective and least invasive.

The recommended interval between surveillance endoscopies depends on the length of the Barrett’s segment and whether dysplasia has been identified. For people with non-dysplastic Barrett’s oesophagus, Australian guidelines recommend follow-up endoscopy every two to three years for long-segment disease and every three to five years for short-segment disease. Where dysplasia is found, surveillance intervals are shortened considerably and management decisions become more complex.

The decision to commence a surveillance programme takes into account individual factors including the person’s age, overall health, and their capacity to participate in a long-term monitoring schedule. Your gastroenterologist will discuss the most appropriate approach for your individual circumstances.

Managing Gastro-Oesophageal Reflux

Controlling acid reflux is an important part of managing Barrett’s Oesophagus. In people with both Barrett’s Oesophagus and ongoing reflux symptoms, acid-suppressing medication is prescribed at a dose sufficient to control symptoms and allow any oesophageal inflammation to heal. Where medication alone does not adequately control reflux or heal oesophagitis, an anti-reflux surgical procedure may be considered in some cases.

It should be noted that there is currently no strong evidence that either medical or surgical treatment of reflux causes the Barrett’s segment to regress substantially or reduces the risk of cancer progression. Management of reflux in this context is primarily aimed at symptom relief and mucosal healing, which in turn allows surveillance biopsies to be interpreted accurately.

When Dysplasia is found

Low Grade Dysplasia

When low grade dysplasia is identified on biopsy, the findings are typically reviewed by a second pathologist, ideally one with expertise in gastrointestinal pathology, to confirm the diagnosis, as there is known variability in how these changes are interpreted. Management options include close monitoring with repeat endoscopy and biopsies every six months, or referral to a centre with specialist expertise in endoscopic assessment and treatment of Barrett’s Oesophagus. The decision is made in the context of the individual patient, taking into account the characteristics of the Barrett’s segment, the patient’s age and fitness, and their preferences.

High Grade Dysplasia

The finding of high grade dysplasia represents a significant change in the Barrett’s segment and warrants referral to a specialist centre with integrated expertise across endoscopy, imaging, and histopathology. A multidisciplinary assessment ensures that the diagnosis is confirmed and that the most appropriate treatment plan is developed. High grade dysplasia is managed endoscopically in most cases where the disease remains confined to the superficial layers of the oesophageal wall.

Endoscopic Treatment Options

Over the past decade, advances in endoscopic technique have transformed the management of dysplasia and early oesophageal adenocarcinoma arising in Barrett’s Oesophagus. Where surgery was previously the only definitive option, it is now possible to treat many cases using minimally invasive endoscopic procedures that preserve the oesophagus and carry substantially lower risk.

Endoscopic Mucosal Resection

Endoscopic mucosal resection is a technique in which abnormal tissue within the Barrett’s segment is removed through the endoscope. The tissue is aspirated into a cap at the tip of the endoscope, secured, and then resected and retrieved for detailed histological examination. This allows accurate assessment of the depth to which abnormal cells have penetrated the oesophageal wall, which is critical for determining whether further treatment is needed.

Radiofrequency Ablation

Radiofrequency ablation delivers controlled thermal energy to the Barrett’s segment through an endoscopically placed electrode, destroying the abnormal mucosal layer. Over time, the treated area is replaced by healthy squamous tissue. Radiofrequency ablation is commonly used to treat the remaining flat Barrett’s segment following endoscopic mucosal resection of visible lesions, and studies have demonstrated durable eradication of dysplasia and metaplasia in the majority of patients treated.

These endoscopic approaches carry a small risk of complications including pain, bleeding, and in rare cases stricture formation, but they are considerably less invasive than surgical alternatives and allow for ongoing endoscopic follow-up.

Lifestyle Considerations

While lifestyle modification alone cannot reverse Barrett’s Oesophagus, certain measures may help to reduce the burden of reflux and support overall gastrointestinal health. Maintaining a healthy weight, particularly reducing central abdominal fat, is beneficial, as is avoiding cigarette smoking. Practical steps such as eating smaller meals, avoiding lying down shortly after eating, and elevating the head of the bed may help reduce the frequency and severity of reflux symptoms. Your gastroenterologist can provide guidance specific to your situation.

Speaking with a Gastroenterologist

If you have been living with persistent reflux, have received a new diagnosis of Barrett’s Oesophagus, or have been told you need further assessment or surveillance, a specialist gastroenterologist is best placed to guide your care. Gastroenterologists have the clinical expertise and procedural skills to perform diagnostic and therapeutic endoscopy, interpret biopsy findings, and work with you to establish an individualised plan for long-term management.

To see a gastroenterologist, you will need a referral from your GP. If you are concerned about ongoing reflux symptoms or have been advised that further investigation is warranted, speak with your GP in the first instance. They can assess your situation and provide a referral to Queensland Gastroenterology.

Our specialist team provides comprehensive assessment and ongoing care for patients with Barrett’s Oesophagus across Brisbane and South East Queensland. Once you have your referral, please contact our practice directly to arrange an appointment.

This information has been sourced and adapted from education and guideline resources developed by the following, as at 21/5/2026:

• Whiteman, D. C., & Kendall, B. J. (2016). Barrett’s oesophagus: epidemiology, diagnosis and clinical management. Medical Journal of Australia, 205(7), 317–324. https://doi.org/10.5694/mja16.00796
• Cancer Council Australia Barrett’s Oesophagus and Early Oesophageal Adenocarcinoma Working Party. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal J Gastroenterol Hepatol. 2015 adenocarcinoma May;30(5):804-20. doi: 10.1111/jgh.12913.
• Better Health Channel Victoria (Better Health Channel)